These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 14726540)
1. Both thrombotic and nonthrombotic cardiovascular and cerebrovascular side effects of nonsteroidal anti-inflammatory drugs should be considered. Stöllberger C; Finsterer J Stroke; 2004 Feb; 35(2):e26. PubMed ID: 14726540 [No Abstract] [Full Text] [Related]
2. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789 [TBL] [Abstract][Full Text] [Related]
3. Increased risk of cardiovascular events with coxibs and NSAIDs. Scott DG; Watts RA Lancet; 2005 Apr 30-May 6; 365(9470):1537. PubMed ID: 15866299 [No Abstract] [Full Text] [Related]
4. Matters of the heart: assessing the cardiovascular safety of new drugs. Konstam MA Am Heart J; 2003 Oct; 146(4):561-2. PubMed ID: 14564304 [No Abstract] [Full Text] [Related]
5. Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders. Stöllberger C; Finsterer J Z Kardiol; 2003 Sep; 92(9):721-9. PubMed ID: 14508588 [TBL] [Abstract][Full Text] [Related]
6. Minimizing cardiovascular complications during the treatment of osteoarthritis. Whelton A; Gibofsky A Am J Ther; 2011 Nov; 18(6):466-76. PubMed ID: 21048434 [TBL] [Abstract][Full Text] [Related]
7. Cardiorenal differences among NSAIDs and coxibs: real-world experience. Sonnenblick EH Am J Manag Care; 2002 Oct; 8(15 Suppl):S369-70. PubMed ID: 12416786 [No Abstract] [Full Text] [Related]
8. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences. Stöllberger C; Finsterer J South Med J; 2004 Feb; 97(2):209. PubMed ID: 14982279 [No Abstract] [Full Text] [Related]
15. Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP. Giannitsis E Clin Lab; 2005; 51(1-2):63-83. PubMed ID: 15719708 [TBL] [Abstract][Full Text] [Related]
16. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790 [TBL] [Abstract][Full Text] [Related]
18. The practice implications of cardiovascular risks in NSAIDs. Hainsworth T Nurs Times; 2005 Jun 28-Jul 4; 101(26):26-7. PubMed ID: 16010838 [TBL] [Abstract][Full Text] [Related]
19. [Alleviating pain and preventing inflammation with selective COX-2 inhibitors. Prescribing with confidence in the future]. MMW Fortschr Med; 2005 Mar; 147(9):12. PubMed ID: 15794346 [No Abstract] [Full Text] [Related]
20. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Schmidt M; Lamberts M; Olsen AM; Fosbøll E; Niessner A; Tamargo J; Rosano G; Agewall S; Kaski JC; Kjeldsen K; Lewis BS; Torp-Pedersen C Eur Heart J; 2016 Apr; 37(13):1015-23. PubMed ID: 26984863 [No Abstract] [Full Text] [Related] [Next] [New Search]